AARD vs BIIB · $284.4M cap vs P/E 21, rev $9.89B
Aardvark Therapeutics, Inc. Common Stock (AARD) versus Biogen Inc (BIIB) — a side-by-side from cached financials, not a winner call.
Aardvark Therapeutics, Inc. Common Stock (AARD) is a biotechnology company listed on US.
Biogen Inc (BIIB) is a drug manufacturers - general company listed on NASDAQ. It is led by Christopher A. Viehbacher.
Latest reported AARD revenue for 2025-12-31 was $0. Net income was -$57.6M. Revenue was down 100.0% from 2024-12-31 to 2025-12-31. AARD currently screens at market cap $284.4M.
Latest reported BIIB revenue for 2025-12-31 was $9.89B. Net income was $1.29B. Revenue was up 2.2% from 2024-12-31 to 2025-12-31. BIIB currently screens at market cap $29.33B and trailing P/E 21.4.
AARD currently screens at market cap $284.4M. BIIB currently screens at market cap $29.33B and trailing P/E 21.4.
Not investment advice. Open the AARD and BIIB stock pages for the full models.
Not investment advice.